Perspective piece asks whether digital health tools can push Lp(a) testing toward the ubiquity of A1C (Front Cardiovasc Med 2025)

This perspective piece argues that Lp(a) testing lags far behind other cardiovascular biomarkers, with an estimated less than 1% of the US population ever screened despite its established link to cardiovascular risk. The authors propose that digital health tools built around behavioural motivation models (COM-B and the Social Ecological Model) could help overcome patient and system inertia to seeking Lp(a) testing. They highlight rising GLP-1 receptor agonist prescribing as a parallel opportunity, since patients already engaged in managing type 2 diabetes and obesity biomarkers through these drugs could be motivated to extend that engagement to Lp(a) and broader cardiovascular risk. The piece frames this behavioural-technology approach as a near-term lever that could meaningfully raise testing rates ahead of, and in preparation for, emerging disease-modifying Lp(a) therapies.